Caption Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-30,000
Closed -$4.59M 1684
2021
Q1
$4.59M Sell
30,000
-38,700
-56% -$5.99M 0.1% 267
2020
Q4
$10.7M Buy
68,700
+43,700
+175% +$5.62M 0.24% 111
2020
Q3
$2.86M Buy
+25,000
New +$2.7M 0.07% 337
2020
Q2
Sell
-30,000
Closed -$2.69M 1266
2020
Q1
$2.69M Buy
30,000
+24,100
+408% +$2.37M 0.15% 187
2019
Q4
$638K Sell
5,900
-19,100
-76% -$2.04M 0.02% 591
2019
Q3
$2.45M Buy
+25,000
New +$2.82M 0.13% 204
2018
Q1
Sell
-29,800
Closed -$3.56M 364
2017
Q4
$3.56M Buy
+29,800
New +$3.63M 0.37% 83

Other funds holding ALXN

Caption Management's ALXN Position: Q2 2021 in Review

Caption Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 18,200 shares — an estimated $2.78M sold.

Caption Management first reported a position in ALXN in Q2 2019 and held it in 8 quarters. The position peaked at $13.4M in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Caption Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Caption Management sold 18,200 Alexion Pharmaceuticals shares in Q2 2021, an estimated $2.78M.
  • Caption Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 8 quarters.
  • Caption Management's Alexion Pharmaceuticals position peaked at $13.4M in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Caption Management's 13F filing for Q2 2021, filed 16 Aug 2021.